Multi-Stakeholder and Collaborative Governance

Sophia Tickell is the co-founder and director of Pharma Futures, a series of investor-led dialogues on how to achieve a better balance between societal and shareholder returns. She is the chairperson of the Expert Review Committee from Access to Medicine Index; chairperson of Medicines Transparency Alliance (MeTA) International Advisory Group; sole external adviser to the Corporate Social Responsibility Committee of GSK’s Board. In addition, she is member of the European Healthcare Innovation Leadership Network; member of the Aviva SRI Advisory Committee; member of Vodafone’s External Experts Forum; member of the Doughty Centre Advisory Council of the Cranfield School of Management; member of the European Healthcare Innovation Leadership Network and provides advice to a number of NGO’s including Oxfam and the Access to Medicine Index.

She is the author of a number of publications, including “The Antibiotic Innovation Study” and “The Pharma Futures reports” and Non-Executive Director SustainAbility.

Dr. Charles Clift is a Senior Adviser in the UK Department for International Development (DFID) on Access to Medicines. From 2001 to 2002, he was head of the Secretariat of the U.K. Commission on Intellectual Property rights. From 2004-2006, he joined the WHO at a similar capacity commission on intellectual Property Rights, Innovation and Public Health.

Hannah Kettler is an economist and senior program officer on the global health advocacy team at the Bill & Melinda Gates Foundation. She is responsible for a portfolio of grants and projects that aim to secure adequate financing and a supportive policy environment for global health product innovation and introduction. Given the important role that for-profit companies in both the north and south play in product development, much of her work is focused on reducing risks, and designing of financial incentives and business models to encourage greater private sector company engagement.

Prior to joining the Gates Foundation, Hannah led a two year Rockefeller Foundation funded project titled “Biotechnology and Global Health” at the Institute for Global Health at the University of California San Francisco. Between 1998 and 2001 Hannah worked as the senior industrial economist for the Office of Health Economics (OHE) in London.

Richard Laing is responsible for editing the Essential Medicines Monitor and for leading the Medicines Information and Evidence for the Policy Team at WHO.
Before that he was professor of International Public Health at Boston University School of Public Health, where he was engaged in working on measurement of medicines pricing and availability, as part of the joint WHO/HAI project on Medicine Prices. Prior to joining the WHO he worked `18 years for the Ministry of Health Zimbabwe. He has published an extensive list of academic papers and is a co-author of standard text “Managing Drug Supply” ,“the Priority Medicines for Europe” and the “World Report”.

Professor Elias Mossialos is director of the health faculty at the London School of Economics. He is also head of the health teaching cluster at the Department of Social Policy. He holds numerous positions including fellow of the Faculty of Public Health and of the Royal College of Physicians and Honorary Consultant in Public Health with the South East London NHS Strategic Health Authority.

In 1998, he co-founded the European Observatory on Health Systems and Policies.
In 2002 and 2007, he was recipient of the Baxter Award from the European Health Management Association for the best publication in health policy and management in Europe.

My Linh Ngo is responsible for sustainability and corporate responsibility analysis and engagement for the SRI funds at Henderson Global Investors. She leads on various engagement initiatives with the Pharmaceutical Industry including Pharmaceutical Shareowners Group (PSG) and the Pharmaceutical Shareowners Forum (PSF). She is also member of the Access to Medicines foundation Advisory Committee, and the GlaxoSmithKline EHS Stakeholder panel.

Dr. Eva Ombaka is currently an honorary pharmaceutical adviser to the World Council of Churches. She is involved in the work of Sustainable Healthcare Enterprises Foundation (SHEF) that has pioneered the franchising of community-based pharmaceutical services to enable access to essential medicines and other basic health services.

She was for coördinator of the Ecumenical Pharmaceutical Network (EPN), where she was active for seventeen years. The EPN brings church-related health services around the world to address pharmaceutical issues together. In 2007, she was the winner of Olle Hansson for 2007 for her work in rational use of medicines.

Former vice President of corporate responsibility at Merck & Co., Inc., in Whitehouse Station, New Jersey, Mr. Sturchio managed a portfolio of activities. He also served as a president of the Merck Company Foundation. Since 2000, he served as a member of the board of the African Comprehensive HIV/AIDS Partnerships in Botswana (2005-2009) and a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria (2002-2008).

Dr. Sturchio is also a Visiting Scholar at the Institute for Applied Economics and the Study of Business Enterprise at The Johns Hopkins University and a member of the World Economic Forum’s Global Agenda Council on the Healthy Next Generation.

Guy Willis leads the gathering of information on research-based pharmaceutical companies’ 200+ programs to improve health in developing countries, amongst other communication activities at IFMPA.

Before joining IFMPA, he managed communications at the International Road Transport Union on products and issues in pharmaceuticals (Serono, now Merck Serono), food packaging (Tetra Pak) and welding (Castolin).

Former CEO Heineken
Chairman STOP AIDS NOW

Secretary-General of the Indian Pharmaceutical Alliance, Co-chairman of the FICCI’s Committee on Pharmaceuticals and Member of the Management Committee of the International Generic Pharmaceutical Alliance (IGPA).

Professor of Medicine at the Academic Medical Center, Director International Aids Therapy Evaluation Center

Director of the Athena Institute for research on innovation and communication in Health and Life Sciences and Professor of Biology and Society at the Vrije Universiteit Amsterdam

Director Pharmaceutical R&D Project, The George Institute for International Health

Founder and former CEO of Innovest Strategic Value Advisors

Professor in Business Ethics and Integrity Management at Erasmus University Rotterdam

Pharmaceutical Shareowners Group, AXA group

Professor of finance, chair in Institutional investments at the University of Maastricht, director of the European Centre for Corporate Engagement

President of Holland Financial Center and board member of PharmAccess and the Health Insurance Fund

Professor Multivariate Statistics, Multicriteria Decision Support, Financial Econometrics, Groningen University. Manager Research & Development, SNS Asset Management.